Close
The article delves into the intersection of artificial intelligence and drug discovery, highlighting the challenges faced by the industry due to exaggerated marketing claims. Despite AI's potential in mapping molecules and predicting their interactions, there is concern over the unrealistic expectations set by the hype surrounding AI in drug development. The CEO of Insitro, Daphne Koller, expressed worries about the overinflated promises of AI breakthroughs in the near future.
The discussion at STAT's Breakthrough Summit in San Francisco emphasized the need to distinguish between the genuine advancements facilitated by AI and the sensationalized portrayals that dominate the narrative. The article underscores the importance of tempering expectations and focusing on the practical applications of AI in drug discovery. By separating the hype from reality, industry experts aim to foster a more grounded approach to leveraging AI technology in the pharmaceutical sector.
The Globe and Mail 13month
Business Insider on MSN.com 8month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.
Log in
Sign Up
AI Tools - Popular
AI Tools - Categories
GPTs - Categories
AI for Jobs
